Effects of a Patient Decision Aid for Nonmetastatic Prostate Cancer Established in Routine Care: The Randomized Controlled EvEnt-PCA Trial
Johannes Huber(Heidelberg University), Christer Groeben(Philipps University of Marburg), Joachim Stein(Klinikum Region Hannover), Philipp Spiegelhalder(Neanderthal Museum), C. Weißflog(Advanced Mask Technology Center (Germany)), Luka Flegar(The Royal Melbourne Hospital), Philipp Karschuck(Heidelberg University), Andreas Ihrig(Heidelberg University), Tanja Krones(University Hospital Zurich), Martin Baunacke(Technische Universität Dresden), Cem Aksoy(Heidelberg University), Christian Klopf(Vivantes Klinikum), Sven von Ahn(Krankenhaus der Barmherzigen Brüder Trier), Georgi Tosev(Heidelberg University), P. Liske(Institut Dr. Flad), Martin Schostak(Aturo), Christian Thomas(Hôpital des Diaconesses), Rainer Koch(Heidelberg University), Andreas Neisius(Trier University of Applied Sciences), Steffen Weikert(St. Hedwig-Krankenhaus), Michael Siebels, Nicolas Haseke(München Klinik), Thomas Benusch(Schön Klinik Neustadt)
Cited by 2
Related Papers
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
Best Practice in Interventional Management of Urolithiasis: An Update from the European Association of Urology Guidelines Panel for Urolithiasis 2022
|European Urology Focus|2022|252
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
|The Lancet Oncology|2016|218
The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma
|European Journal of Cancer|2010|187
Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas
|International Journal of Molecular Medicine|2005|151